Recent studies show that in the treatment of HCC, the combination of IL6 blockers and immunosuppressants can improve the tumor microenvironment, enhance the antitumor effect, and reduce the side effects caused by immunosuppressants.36 This evidence concerns the gene IL6 and hepatocellular carcinoma.